Participants 73 145 3
patients with severe chronic congestive heart failure: the PROMISE Study
Participants 263 320 3
patients with moderate to severe congestive heart failure
Participants 591 765 5
1,068 patients enrolled in a survival study of class III or IV heart failure at the time of double-blind randomization to milrinone, a phosphodiesterase inhibitor, or placebo
